263 related articles for article (PubMed ID: 11391628)
1. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
3. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten AA; Snijdewint FG; van Kamp GJ; Schol DJ; Reis CA; Price MR; Livingston PO; Hilgers J
Int J Cancer; 2000 Jun; 86(5):702-12. PubMed ID: 10797294
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
5. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
6. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.
Van Elssen CH; Clausen H; Germeraad WT; Bennet EP; Menheere PP; Bos GM; Vanderlocht J
J Immunol Methods; 2011 Feb; 365(1-2):87-94. PubMed ID: 21194532
[TBL] [Abstract][Full Text] [Related]
9. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
[TBL] [Abstract][Full Text] [Related]
10. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
[TBL] [Abstract][Full Text] [Related]
11. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
[TBL] [Abstract][Full Text] [Related]
12. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
13. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
14. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
15. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
16. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
17. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
Ciborowski P; Finn OJ
Clin Exp Metastasis; 2002; 19(4):339-45. PubMed ID: 12090474
[TBL] [Abstract][Full Text] [Related]
18. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
19. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells.
Persson J; Bäckström M; Johansson H; Jirström K; Hansson GC; Ohlin M
Tumour Biol; 2009; 30(4):221-31. PubMed ID: 19776674
[TBL] [Abstract][Full Text] [Related]
20. Context of MUC1 epitope: immunogenicity.
Quinlin IS; Burnside JS; Dombrowski KE; Phillips CA; Dolby N; Wright SE
Oncol Rep; 2007 Feb; 17(2):453-6. PubMed ID: 17203187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
